alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - 21 CFR Chapter I

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Final rule; technical amendment.

# SUMMARY:

The Food and Drug Administration (FDA) is amending its regulations to reflect a change in the address for the American Society for Testing Materials (ASTM). This action is editorial in nature and is intended to improve the accuracy of the agency's regulations.

# DATES:

This rule is effective December 1, 2005.

# FOR FURTHER INFORMATION CONTACT:

Joyce Strong, Office of Policy and Planning (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

# SUPPLEMENTARY INFORMATION:

This document amends FDA's regulations to reflect the address change of ASTM by removing the outdated address wherever it appears and by adding the new address in its place in 21 CFR parts 172, 175, 176, 177, 178, and 179.

Publication of this document constitutes final action on these changes under the Administrative Procedure Act (5 U.S.C. 553). Notice and public procedure are unnecessary because FDA is merely correcting nonsubstantive errors.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR chapter I is amended as follows:

# Chapter I [Nomenclature changes]

1. Parts 172, 175, 176, 177, 178, and 179 are amended by removing “1916 Race St., Philadelphia, PA 19103” or “1916 Race Street, Philadelphia, PA 19103” and adding in its place “100 Barr Harbor Dr., West Conshohocken, Philadelphia, PA 19428-2959” wherever it appears. 

Dated: November 23, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 05-23521 Filed 11-30-05; 8:45 am]

BILLING CODE 4160-01-S
Case 1:07-cv-03582-LLS     Document 200      Filed 03/31/2010     Page 1 of 1
#### JOHNSON v. MASSENGILL

No. 11 PC.

Case below: 12 N.C. App. 6.

Petition for writ of *certiorari*to North Carolina Court of Appeals allowed 5 October 1971.
[Federal Register Volume 72, Number 199 (Tuesday, October 16, 2007)]
[Notices]
[Pages 58671-58672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-5086]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; Alzheimer Pathogenesis.
    Date: October 24, 2007.
    Time: 9 a.m. to 12 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, 2C212, Bethesda, MD 20814 (Telephone Conference 
Call).
    Contact Person: William Cruce, PhD, Health Scientist 
Administrator, Scientific Review Office, National Institute on 
Aging, National Institutes of Health, Room 2C212, 7201 Wisconsin 
Avenue, Bethesda, MD 20814, 301-402-7704, <a href="/cdn-cgi/l/email-protection#80e3f2f5e3e5f7c0eee9e1aeeee9e8aee7eff6"><span class="__cf_email__" data-cfemail="b5d6c7c0d6d0c2f5dbdcd49bdbdcdd9bd2dac3">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)


[[Page 58672]]


    Dated: October 5, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-5086 Filed 10-15-07; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          FEB-28-1999
<PERIOD-END>                               NOV-30-1998
<CASH>                                          422620
<SECURITIES>                                         0
<RECEIVABLES>                                    13214
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                425212
<PP&E>                                             360
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  436194
<CURRENT-LIABILITIES>                             4380
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        205995
<OTHER-SE>                                      225819
<TOTAL-LIABILITY-AND-EQUITY>                    436194
<SALES>                                              0
<TOTAL-REVENUES>                                 38202
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               (58756)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (20554)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
**Exhibit 32.2**

 

**CERTIFICATIONS PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**(18 U.S.C. SECTION 1350)**

 

In connection with the Annual Report of U.S. MEDSYS CORP. (the “Company”) on Form10-KSB for the period ending June 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Rubino , Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C.§ 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: 

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 

 

(2) The information contained in the Report fairly presents, in all materialrespects, the financial condition and result of operations of the Company. 

 

Dated: November 15, 2005
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Heart, Lung, and Blood Institute Special Emphasis Panel; Short Term Research Education Program (R25's).                    

*Date:*                         October 22, 2007.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.                    

*Contact Person:*                         Rina Das, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7200, Bethesda, MD 20892-7294, (301) 435-0297,                         *dasr2@nhlbi.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 98.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 19, 2007.

Jennifer Spaeth, 

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07-4810  Filed 09-28-07; 8:45 am]

BILLING CODE 4140-01-M
Case 1:07-cv-03419-AKH     Document 24      Filed 02/08/2008     Page 1 of 1
CERTIFICATION

I, Derek L. Caldwell, President and Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Lincoln International
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

                                                   /s/ DEREK L. CALDWELL
                                                   -----------------------------
                                                   Name:  Derek L. Caldwell
                                                   Title: President
                                                   Date:  July 22, 2005
Amendment No. 2 to the Amended 2000 Employee Stock Purchase Plan



 Exhibit 10.2 
 AMENDMENT NO. 2 TO THE MARVELL TECHNOLOGY GROUP LTD. 
 AMENDED 2000 EMPLOYEE STOCK PURCHASE PLAN

 The Marvell Technology Group Ltd. Amended 2000 Employee Stock Purchase Plan (the “Plan”) is hereby amended effective
June 10, 2009, as follows: 
 1.      Section 12(a)(ii) of the Plan is amended to provide in its
entirety as follows: 
 “(ii) Beginning the first business day of each calendar year starting January 1, 2010 or after, the lesser
of an additional (A) 8,000,000 shares of Common Stock, or (B) 1.5% of the outstanding shares of capital stock on such date, or (C) an amount determined by the Board (provided that the amount approved by the Board shall not be greater
than (A) or (B)).”
Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 1 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 2 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 3 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 4 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 5 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 6 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 7 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 8 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 9 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 10 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 11 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 12 of 13

Case 1:07-cv-03383-PAC     Document 7      Filed 05/23/2007     Page 13 of 13
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 1 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 2 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 3 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 4 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 5 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 6 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 7 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 8 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 9 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 10 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 11 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 12 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 13 of 14
Case 1:07-cv-03496-WHP Document 17-5 Filed 06/26/2007 Page 14 of 14
EXHIBIT 31.1  CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindsay Semple, certify that: 1. I have reviewed this I have reviewed this annual report on Form 10KSB for the fiscal year ended December 31, 2005, of Global Precision Medical Inc.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report. 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have: a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and c) disclosed in this report any change in the small business issuer's internal control over      financial reporting that occurred during the registrant's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and 5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrants auditors and the audit committee of the Registrants board of directors (or persons performing the equivalent functions): a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's  ability to record, process, summarize and report financial information; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's  internal control over financial reporting.  Date: March 12, 2007 /s/ Lindsay Semple Lindsay Semple Chief Executive Officer and Acting Chief Financial Officer
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                                    1,000
<CURRENCY>                               U.S. Dollars
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                         NOV-29-1997
<PERIOD-END>                              MAR-01-1997
<EXCHANGE-RATE>                                 1.000
<CASH>                                            332
<SECURITIES>                                        0
<RECEIVABLES>                                  11,910
<ALLOWANCES>                                     (226)
<INVENTORY>                                    27,864
<CURRENT-ASSETS>                               44,105
<PP&E>                                         17,990
<DEPRECIATION>                                  8,587
<TOTAL-ASSETS>                                 60,578
<CURRENT-LIABILITIES>                          22,251
<BONDS>                                             0
<PREFERRED-MANDATORY>                           4,249
<PREFERRED>                                         0
<COMMON>                                            0 
<OTHER-SE>                                     31,567
<TOTAL-LIABILITY-AND-EQUITY>                   60,578
<SALES>                                         8,624
<TOTAL-REVENUES>                                8,624
<CGS>                                           6,570
<TOTAL-COSTS>                                   6,570
<OTHER-EXPENSES>                                1,904
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                                376
<INCOME-PRETAX>                                   150
<INCOME-TAX>                                       52
<INCOME-CONTINUING>                                 0
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                       98
<EPS-PRIMARY>                                     .03
<EPS-DILUTED>                                       0
        

</TABLE>
#### STATE v. EFIRD

No. 106 PC

Case below: 49 NC App

Petition by defendant for discretionary review under G.S. 7A-31 denied 2 December 1980.